{"id":"NCT03777436","sponsor":"Amgen","briefTitle":"An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double Blind-Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-11","primaryCompletion":"2021-09-23","completion":"2022-02-09","firstPosted":"2018-12-17","resultsPosted":"2022-12-15","lastUpdate":"2024-05-14"},"enrollment":289,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Apremilast","otherNames":["CC-10004, Otezla"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A- Apremilast with Placebo","type":"EXPERIMENTAL"},{"label":"Arm B - Apremilast 30 mg","type":"EXPERIMENTAL"}],"summary":"This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G â‰¥3, moderate or severe).\n\nApproximately 286 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.","primaryOutcome":{"measure":"Percentage of Participants With a Modified sPGA-G Response at Week 16","timeFrame":"Baseline and Week 16 of the Placebo-controlled Phase","effectByArm":[{"arm":"Placebo-controlled Phase: Placebo","deltaMin":19.5,"sd":null},{"arm":"Placebo-controlled Phase: Apremilast 30 mg","deltaMin":39.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States","Belgium","Canada","France","Germany","Italy","Puerto Rico"]},"refs":{"pmids":["37852306"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":145},"commonTop":["Diarrhoea","Headache","Nausea","Nasopharyngitis"]}}